Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can PrEP stop HIV in west african men? new study says yes, it's feasible.

NCT ID NCT03459157

Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether men who have sex with men (MSM) in Burkina Faso, Côte d'Ivoire, Mali, and Togo would accept and use PrEP (a daily or on-demand pill) to prevent HIV. Over 600 HIV-negative men at high risk took part, receiving regular check-ups, STI testing, and support. The goal was to see if PrEP is practical and effective in real-world community clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

649 people

The number who actually took part.

Started

Nov 2017

Finished

Jun 2021

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male (or transgender male person at birth) * At least 18 years old * HIV-seronegative * Having had at least one anal sex episode with another man within the previous 6 months * Having at least one of the following criteria: * Have a sexual partner (male or female) infected with HIV without evidence of virological suppression * Have had anal or vaginal sex episodes without condoms with more than one partner within the previous 6 months * Have had a sexually-transmitted infection (STI) within the previous 6 months (syndromic or biological approach, or mentioned by the participant) * Have received post-exposure prophylaxis for HIV within the previous 6 months * Wishing to reinforce its means of prevention through the use of PrEP * Accepting to participate in the study and signing the informed consent form Exclusion Criteria: * Clinical manifestations suggesting a primary HIV infection * Recent probable HIV exposure * Creatinine clearance \<60 mL/min calculated according to the Cockroft \& Gault formula * Positive or undetermined HBsAg * Allergy or contraindication to any of the components of PrEP * Participation in another biomedical and/or behavioral study on HIV or STIs (excluding CohMSM) * Disability of the person making it difficult, if not impossible, to participate in the study or understanding of the information given to him * Predictable non-compliance with the protocol (geographical distance, non-compliance with monitoring or other reasons)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS Homosexuality HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV/AIDS

Contacts and locations

Locations

  • Centre Lucia, Espoir Vie Togo

    Lomé, Togo

  • Centre Oasis, Association African Solidarité

    Ouagadougou, Burkina Faso

  • Clinique de Confiance, Espace Confiance

    Abidjan, Côte d’Ivoire

  • Clinique des Halles, ARCAD-SIDA

    Bamako, Mali

More trials for these conditions

Other studies related to the condition(s) this trial covers.